一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫检查点阻断耐药仍是非小细胞肺癌(NSCLC)患者面临的挑战。肿瘤浸润白细胞(TIL)的数量、组成和活化状态会显著影响癌症免疫治疗应答。本研究分析281份新鲜切除的NSCLC组织中的TIL特征,以考察NSCLC肿瘤微环境的免疫图谱。研究依据30种TIL类型的数量和比例进行无监督聚类,将肺腺癌(LUAD)和肺鳞状细胞癌(LUSQ)分为免疫冷型、髓系细胞占优势型和CD8+ T细胞占优势型。这些亚型与患者预后显著相关,其中髓系细胞型结局较差。整合基因组和转录组分析(包括RNA测序、全外显子组测序、T细胞受体谱及肿瘤组织代谢组学)显示,免疫反应相关信号通路在LUAD和LUSQ髓系细胞型中失活,而糖酵解和K-Ras信号通路活化。ALK和ROS1融合基因病例在LUAD髓系细胞型中富集;LUSQ髓系细胞型的TERT拷贝数变异频率高于其他亚型。按TIL状态对NSCLC分类,可能有助于开发个体化免疫治疗。意义:精确的TIL分析将NSCLC分为与患者结局相关的三种新免疫亚型,并识别亚型特异性分子通路和基因组改变;这些特征可能参与形成相应的肿瘤免疫微环境,也可为个体化治疗提供依据。
UNLABELLED: Resistance to immune checkpoint blockade remains challenging in patients with non-small cell lung cancer (NSCLC). Tumor-infiltrating leukocyte (TIL) quantity, composition, and activation status profoundly influence responsiveness to cancer immunotherapy.
This study examined the immune landscape in the NSCLC tumor microenvironment by analyzing TIL profiles of 281 fresh resected NSCLC tissues. Unsupervised clustering based on numbers and percentages of 30 TIL types classified adenocarcinoma (LUAD) and squamous cell carcinoma (LUSQ) into the cold, myeloid cell-dominant, and CD8 + T cell-dominant subtypes. These were significantly correlated with patient prognosis; the myeloid cell subtype had worse outcomes than the others. Integrated genomic and transcriptomic analyses, including RNA sequencing, whole-exome sequencing, T-cell receptor repertoire, and metabolomics of tumor tissue, revealed that immune reaction-related signaling pathways were inactivated, while the glycolysis and K-ras signaling pathways activated in LUAD and LUSQ myeloid cell subtypes.
Cases with ALK and ROS1 fusion genes were enriched in the LUAD myeloid subtype, and the frequency of TERT copy-number variations was higher in LUSQ myeloid subtype than in the others. These classifications of NSCLC based on TIL status may be useful for developing personalized immune therapies for NSCLC.
SIGNIFICANCE: The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。